Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918861 · ClinicalTrials.gov registry record · Phase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
A Phase 3 study of Acute Coronary Syndrome, sponsored by DalCor Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
- 20
- Study locations
NCT05918861 is a Phase 3 study of Acute Coronary Syndrome that is actively recruiting participants, run by DalCor Pharmaceuticals. The registered enrollment target is 2,000 participants, below the 2,672-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT05918861, a Phase 3 study of Acute Coronary Syndrome, is actively recruiting participants, sponsored by DalCor Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may begin in the hospital and will continue following release from the hospital or may begin following release from hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (up to12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dalcetrapib
Study Locations (20)
California
- Research Site - Garden Grove
- Research Site - Huntington Beach
- Research Site - La Jolla
- Research Site - Long Beach
- Research Site - Los Angeles
- Research Site - Newport Beach
- Research Site - Newport Beach
- Research Site - San Francisco
- Research Site - Santa Barbara
- Research Site - Stanford
- Research Site - Torrance
Alabama
- Research Site - Alexander City
- Research Site - Birmingham
- Research Site - Fairhope
- Research Site - Huntsville
- Research Site - Mobile
Arizona
- Research Site - Scottsdale
- Research Site - Tucson
Arkansas
- Research Site - Jonesboro
- Research Site - North Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05918861
The ClinicalTrials.gov registry entry for NCT05918861 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,672-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (25% lower). The listed sponsor is DalCor Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05918861 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05918861 about?
NCT05918861 is a clinical study titled "Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS". This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent...
What is the current status of trial NCT05918861?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2023-10-03. Estimated completion is 2027-08.
What conditions does trial NCT05918861 study?
This clinical trial studies the following conditions: Acute Coronary Syndrome.
What interventions are being tested in trial NCT05918861?
The interventions under investigation include: Placebo (DRUG), Dalcetrapib (DRUG).
Who is sponsoring clinical trial NCT05918861?
This trial is sponsored by DalCor Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918861 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
COMPLETED · Phase 3
-
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
COMPLETED · Phase 3
-
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
COMPLETED · Phase 3
-
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
COMPLETED · Phase 3
-
A Polypill for Acute Coronary Syndrome
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.